Abstract 4CPS-132 Table 1
Reduction of ≥
50%
migraine days/month (ARR (95%
CI))
Erenumab 70
mg
Erenumab 140
mg
Fremanezumab quarterly
3 (−7.56 to 13.56)
2 (−8.64 to 12.64)
Fremanezumab monthly
6 (−4.59 to 16.59)
5 (−5.66 to 15.66)